CN Patent

CN116744925A — 用四氢萘衍生物作为雌激素受体降解剂治疗乳腺癌的方法

Assigned to Arvinas Inc · Expires 2023-09-12 · 3y expired

What this patent protects

本申请涉及治疗和/或预防需要治疗的受试者的乳腺癌，包含局部晚期或转移性ER+、HER2‑乳腺癌，所述治疗和/或所述预防包括施用式(I)化合物，或其药学上可接受的盐、对映异构体、立体异构体、溶剂化物、多晶型物、同位素衍生物或前药，其中R 1 、R 2 、R 3 、R 4 、m和n在本文定义。

USPTO Abstract

本申请涉及治疗和/或预防需要治疗的受试者的乳腺癌，包含局部晚期或转移性ER+、HER2‑乳腺癌，所述治疗和/或所述预防包括施用式(I)化合物，或其药学上可接受的盐、对映异构体、立体异构体、溶剂化物、多晶型物、同位素衍生物或前药，其中R 1 、R 2 、R 3 、R 4 、m和n在本文定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN116744925A
Jurisdiction
CN
Classification
—
Expires
2023-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Arvinas Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.